Documented concern based on cited evidence — not a personalized safety check, not medical advice, and not a decision to combine or avoid. That decision belongs with your prescriber.

Documented concern — monitor and disclose

Clinically relevant documented concern. Disclose the supplement to your clinician and keep monitoring in place.

Mechanism and evidence

Both lower blood glucose through different pathways: GLP-1 agonists via the incretin signal and appetite, berberine via insulin sensitivity and AMPK. The concern is additive glucose lowering, primarily when insulin or a sulfonylurea is also part of the regimen.

Evidence tier: pharmacology-standard

The tier names the strongest cited study design. Some anchors studied the supplement on its own, or a related drug in the same class — in those pairs the grade rests on that evidence plus established pharmacology, as agreed with our medical reviewer.

What to discuss with your prescriber

  • Do not add berberine on top of a GLP-1 medication without telling your prescriber.
  • If your doctor approves, glucose monitoring may need to be more frequent.

← All reviewed pairs for GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide)